Evolution of Drug Development: Integrating the Patient Perspective Into Early Research

被引:0
|
作者
Yanni, Anthony J. [1 ]
Fine, Jennifer [2 ]
机构
[1] Sanofi R&D, Med Intelligence & Patient Perspect, 55 Corp Dr, Bridgewater, NJ 08807 USA
[2] Sanofi R&D, Med Intelligence & Patient Perspect, Chilly Mazarin, France
关键词
patient perspective; unmet need; medical value; risk/opportunity assessment; medical intelligence;
D O I
10.1177/2168479017716492
中图分类号
R-058 [];
学科分类号
摘要
Soaring drug development costs, increasingly stringent regulatory requirements, and demanding market access environments have necessitated that pharmaceutical companies examine their research processes in order to provide novel and meaningful solutions for patients. In this paper, we describe an initiative that aims to incorporate a better appreciation of the exam room experience of both patients and practitioners into the drug development pathway from the earliest point of research. Focusing on 4 core pillarsmedical value, patient need, scientific rationale, and market environmentan integrated analytic process is undertaken so as to facilitate early identification of ideal target populations and criteria that will need to be met for successful entry into the treatment continuum. Collaborative interactions with other specialist roles within the organization are also described. It is argued that understanding the unmet medical need and the risks and opportunities inherent in different development scenarios can help direct early research so as to encourage truly transformative health care solutions.
引用
收藏
页码:89 / 93
页数:5
相关论文
共 50 条
  • [31] Contract Research Organizations (CROs) in China: integrating Chinese research and development capabilities for global drug innovation
    Shi, Yun-Zhen
    Hu, Hao
    Wang, Chunming
    GLOBALIZATION AND HEALTH, 2014, 10
  • [32] Contract Research Organizations (CROs) in China: integrating Chinese research and development capabilities for global drug innovation
    Yun-Zhen Shi
    Hao Hu
    Chunming Wang
    Globalization and Health, 10
  • [33] The Food and Drug Administration is Listening: Integrating the Voice of the Patient in Drug Development for Parkinson's and Huntington's Diseases
    Stephenson, Diane
    Romero, Klaus
    Podskalny, Gerald
    Bastings, Eric
    Dunn, Billy
    Goldstein, Susanne
    Mullin, Theresa
    NEUROTHERAPEUTICS, 2018, 15 (01) : 255 - 256
  • [34] ADDME – Avoiding Drug Development Mistakes Early: central nervous system drug discovery perspective
    Katya Tsaioun
    Michel Bottlaender
    Aloise Mabondzo
    BMC Neurology, 9
  • [35] ADDME - Avoiding Drug Development Mistakes Early: central nervous system drug discovery perspective
    Tsaioun, Katya
    Bottlaender, Michel
    Mabondzo, Aloise
    BMC NEUROLOGY, 2009, 9
  • [36] Integrating real-world data to accelerate and guide drug development: A clinical pharmacology perspective
    Zhao, Xiaochen
    Iqbal, Shahed
    Valdes, Ivelisse L.
    Dresser, Mark
    Girish, Sandhya
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (10): : 2293 - 2302
  • [37] CHRONOBIOLOGY - SUGGESTIONS FOR INTEGRATING IT INTO DRUG DEVELOPMENT
    HARTER, JG
    PECK, CC
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES-SERIES, 1991, 618 : 563 - 571
  • [38] INTEGRATING VIRTUAL AND HIGH-THROUGHPUT SCREENING: OPPORTUNITIES AND CHALLENGES IN DRUG RESEARCH AND DEVELOPMENT
    Ferreira, Rafaela S.
    Oliva, Glaucius
    Andricopulo, Adriano D.
    QUIMICA NOVA, 2011, 34 (10): : 1770 - 1778
  • [39] Unveiling changes in the landscape of patient populations in cancer early drug development
    Hierro, Cinta
    Azaro, Analia
    Argiles, Guillem
    Elez, Elena
    Gomez, Patricia
    Carles, Joan
    Rodon, Jordi
    ONCOTARGET, 2017, 8 (08) : 14158 - 14172
  • [40] Generation of patient-reported outcomes during early drug development
    Cleeland, C.
    Cuffel, B.
    Keating, K.
    Childs, B.
    Walsh, D.
    Williams, L.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S64 - S64